Skip to content

Research

Published findings, in context.

Each finding is shown with the evidence level at which it was observed. A result in an animal model or in cell culture is not a result in humans.

More filters (study type, organism, year)
Publication year

2 publications

Compounds filed under Tissue damage models · Controlled study in humans

  • Human, controlledControlled study in humans· Homo sapiens

    Randomized human trial of finished products with and without GHK-Cu: blinded objective assessments and a self-rated questionnaire

    Miller TR, Wagner JD, Baack BR, et al.Archives of Facial Plastic Surgery2006PMID 16847171 (opens PubMed in a new tab)Title on PubMedDOI 10.1001/archfaci.8.4.252 (opens the publisher record in a new tab)

    Filed under GHK-Cu

    Model
    Randomized trial of finished products with or without GHK-Cu, assessed at 12 weeks by computer-assisted analysis, blinded evaluators and a self-rated questionnaire
    Sample size
    13
    Exposure
    Finished products containing GHK-Cu
    Comparator
    Finished products without GHK-Cu

    Thirteen participants completed the study. Computer-assisted analysis and blinded evaluators found no differences between the groups on the trial's objective measures at 12 weeks; only a self-rated questionnaire showed a difference between the groups (p = 0.04). The trial used finished products, not research material.

  • Human, controlledControlled study in humans· Homo sapiens

    Randomized, evaluator-blinded human trial: a finished tripeptide-copper formulation, an active comparator and an inert vehicle

    Bishop JB, Phillips LG, Mustoe TA, et al.Journal of Vascular Surgery1992PMID 1495150 (opens PubMed in a new tab)Title on PubMedDOI 10.1067/mva.1992.37086 (opens the publisher record in a new tab)

    Filed under GHK-Cu

    Model
    Prospective, randomized, evaluator-blinded trial of three finished formulations
    Sample size
    86
    Exposure
    Finished formulation containing a tripeptide-copper complex
    Comparator
    Active comparator formulation; inert vehicle (placebo)

    Among 86 evaluable participants, the active comparator outperformed both the tripeptide-copper formulation and the inert vehicle on the trial's primary measure, and no advantage of the tripeptide-copper formulation over the vehicle was reported. The trial used a finished formulation, not research material.

For laboratory research use only. Not for human or veterinary use or consumption. Not for diagnostic use. Not evaluated by the U.S. FDA.